Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

744
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
744
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

97
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
97
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

502
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
502
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

120
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
120
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

82
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
82

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Fluorine-18-Labeled Nucleotide Analogs Targeting Ecto-5'-Nucleotidase (CD73) for Positron Emission Tomography Imaging of Solid Tumors.

Angewandte Chemie (International ed. in English)·2026
Same author

5'-Ectonucleotidase (CD73) inhibitors: a patent review (2021-present).

Expert opinion on therapeutic patents·2026
Same author

Recent advances in factor XII(a) inhibitors: an updated patent landscape (2020-present).

Expert opinion on therapeutic patents·2026
Same author

SMARTDock: A Toolkit for the Automated Development of Target-Specific Scoring Functions Using Bioactivity Data.

Journal of chemical information and modeling·2026
Same author

Collaborative Synthesis for Neglected Diseases through the Open Synthesis Network: Structure-Activity Relationships of Arylaminopyrazoles as Chagas Disease Treatments.

ACS infectious diseases·2025
Same author

Many Faces: The Global Landscape of Medicinal Chemistry.

ACS medicinal chemistry letters·2025
Same journal

USFDA-Approved Small Molecules in the Year 2025: Medicinal Chemistry Strategies and Trends.

Archiv der Pharmazie·2026
Same journal

Triazole-Sulfonamide Hybrids as Carbonic Anhydrase Inhibitors: Emerging Chemistry and Bioactivity Insights From 2020 to 2025.

Archiv der Pharmazie·2026
Same journal

Cholesterol and Cholesterol-Derived Molecules Differentially Modulate Neuronal Kv7.2/7.3 Channels.

Archiv der Pharmazie·2026
Same journal

Channel Dysfunction as the Basis for Comorbidities in Multiple Sclerosis and Depression.

Archiv der Pharmazie·2026
Same journal

K<sub>v</sub>7 and K<sub>2P</sub> Potassium Channels in Thalamocortical Function and Their Therapeutic Potential in Childhood Absence Epilepsy.

Archiv der Pharmazie·2026
Same journal

Silymarin and Its Isolated Flavanonol Lignans Are Liver X Receptor Antagonists.

Archiv der Pharmazie·2026
查看所有相关文章

相关实验视频

Updated: May 7, 2025

Proteomics to Identify Proteins Interacting with P2X2 Ligand-Gated Cation Channels
16:36

Proteomics to Identify Proteins Interacting with P2X2 Ligand-Gated Cation Channels

Published on: May 18, 2009

14.6K

基于皮佩拉的P2X4受体对手.

Katharina Sophie Erlitz1,2, Alena I Siutkina3, Ann-Kathrin Prinz3

  • 1European Institute for Molecular Imaging (EIMI), University of Muenster, Muenster, Germany.

Archiv der Pharmazie
|December 31, 2024
PubMed
概括
此摘要是机器生成的。

研究人员开发了基于皮佩拉的新型抗剂,向P2X4受体 (P2X4R),这是神经炎症和疼痛的关键参与者. 一些化合物与帕洛克塞丁相比,显示出优越的P2X4R对抗性,表明治疗潜力.

关键词:
布赫瓦尔德反应是一种反应.查姆 - 埃文斯 - 拉姆合器一个P2X4受体.这是一种P2X4R抗剂.链接离子通道链接离子通道

更多相关视频

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.5K
Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

11.4K

相关实验视频

Last Updated: May 7, 2025

Proteomics to Identify Proteins Interacting with P2X2 Ligand-Gated Cation Channels
16:36

Proteomics to Identify Proteins Interacting with P2X2 Ligand-Gated Cation Channels

Published on: May 18, 2009

14.6K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.5K
Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

11.4K

科学领域:

  • 神经科学是一个神经科学.
  • 药理学 药理学是指药理学的学科.
  • 药用化学 医学化学

背景情况:

  • P2X4受体 (P2X4R) 与神经炎症,慢性疼痛和癌症有关.
  • P2X4R对抗性代表了这些疾病的潜在治疗策略.
  • 帕洛西丁作为P2X4R抗体发展的参考化合物.

研究的目的:

  • 设计和合成基于皮佩拉的新型P2X4R抗剂.
  • 研究这些化合物的结构-活性关系 (SARs).
  • 为了识别具有改善P2X4R抗作用力的化合物.

主要方法:

  • 合成超过35种基于皮佩拉津的化合物.
  • 使用Ca2+-流量试验评估P2X4R对抗活性.
  • 吸收,分布,新陈代谢和分泌 (ADME) 属性的评估.

主要成果:

  • 几种合成的化合物表现出比帕洛克塞丁更高的P2X4R抗作用力.
  • 增加的脂性与高血蛋白结合和降低的代谢稳定性相关.
  • 含有纳夫他林-2-氧基组的化合物表现出特殊的代谢负债.

结论:

  • 对于基于皮佩拉津的P2X4R抗剂,已经确定了有前途的SAR.
  • 需要进一步优化以提高功效和改善药理动力学特性.
  • 这项研究为开发针对P2X4R的治疗方法提供了基础.